292 related articles for article (PubMed ID: 30050154)
1. L1CAM further stratifies endometrial carcinoma patients with no specific molecular risk profile.
Kommoss FK; Karnezis AN; Kommoss F; Talhouk A; Taran FA; Staebler A; Gilks CB; Huntsman DG; Krämer B; Brucker SY; McAlpine JN; Kommoss S
Br J Cancer; 2018 Aug; 119(4):480-486. PubMed ID: 30050154
[TBL] [Abstract][Full Text] [Related]
2. Prognostic significance of L1CAM expression in addition to ProMisE in endometrial cancer.
Kim J; Kim SI; Kim NR; Kim H; Kim HS; Chung HH; Kim JW; Lee C; Lee M
Gynecol Oncol; 2023 Jul; 174():231-238. PubMed ID: 37236032
[TBL] [Abstract][Full Text] [Related]
3. L1 cell adhesion molecule is a strong predictor for distant recurrence and overall survival in early stage endometrial cancer: pooled PORTEC trial results.
Bosse T; Nout RA; Stelloo E; Dreef E; Nijman HW; Jürgenliemk-Schulz IM; Jobsen JJ; Creutzberg CL; Smit VT
Eur J Cancer; 2014 Oct; 50(15):2602-10. PubMed ID: 25126672
[TBL] [Abstract][Full Text] [Related]
4. Assessment of DNA Ploidy in the ProMisE molecular subgroups of endometrial cancer.
Proctor L; Pradhan M; Leung S; Cheng A; Lee CH; Soslow RA; Gilks CB; Talhouk A; McAlpine JM; Danielsen HE; Hoang LN
Gynecol Oncol; 2017 Sep; 146(3):596-602. PubMed ID: 28647100
[TBL] [Abstract][Full Text] [Related]
5. L1CAM: amending the "low-risk" category in endometrial carcinoma.
Kommoss F; Kommoss F; Grevenkamp F; Bunz AK; Taran FA; Fend F; Brucker SY; Wallwiener D; Schönfisch B; Greif K; Lax S; Staebler A; Kommoss S
J Cancer Res Clin Oncol; 2017 Feb; 143(2):255-262. PubMed ID: 27695947
[TBL] [Abstract][Full Text] [Related]
6. Confirmation of ProMisE: A simple, genomics-based clinical classifier for endometrial cancer.
Talhouk A; McConechy MK; Leung S; Yang W; Lum A; Senz J; Boyd N; Pike J; Anglesio M; Kwon JS; Karnezis AN; Huntsman DG; Gilks CB; McAlpine JN
Cancer; 2017 Mar; 123(5):802-813. PubMed ID: 28061006
[TBL] [Abstract][Full Text] [Related]
7. Endometrial cancer prognosis correlates with the expression of L1CAM and miR34a biomarkers.
Corrado G; Laquintana V; Loria R; Carosi M; de Salvo L; Sperduti I; Zampa A; Cicchillitti L; Piaggio G; Cutillo G; Falcioni R; Vizza E
J Exp Clin Cancer Res; 2018 Jul; 37(1):139. PubMed ID: 29980240
[TBL] [Abstract][Full Text] [Related]
8. Immunohistochemical biomarkers are prognostic relevant in addition to the ESMO-ESGO-ESTRO risk classification in endometrial cancer.
Vrede SW; van Weelden WJ; Visser NCM; Bulten J; van der Putten LJM; van de Vijver K; Santacana M; Colas E; Gil-Moreno A; Moiola CP; Mancebo G; Krakstad C; Trovik J; Haldorsen IS; Huvila J; Koskas M; Weinberger V; Bednarikova M; Hausnerova J; van der Wurff AA; Matias-Guiu X; Amant F; ; Snijders MPLM; Küsters-Vandevelde HVN; Reijnen C; Pijnenborg JMA
Gynecol Oncol; 2021 Jun; 161(3):787-794. PubMed ID: 33858677
[TBL] [Abstract][Full Text] [Related]
9. Prognostic significance of L1CAM expression and its association with mutant p53 expression in high-risk endometrial cancer.
Van Gool IC; Stelloo E; Nout RA; Nijman HW; Edmondson RJ; Church DN; MacKay HJ; Leary A; Powell ME; Mileshkin L; Creutzberg CL; Smit VT; Bosse T
Mod Pathol; 2016 Feb; 29(2):174-81. PubMed ID: 26743472
[TBL] [Abstract][Full Text] [Related]
10. Disseminated tumor cells are not associated with established risk factors, L1CAM immunoreactivity and outcome in endometrial carcinoma.
Kommoss S; Hartkopf AD; Krämer B; Bunz AK; Grevenkamp F; Kommoss F; Pasternak J; Arbabi SM; Wallwiener M; Staebler A; Lax SF; Brucker SY; Taran FA
J Cancer Res Clin Oncol; 2017 Nov; 143(11):2183-2188. PubMed ID: 28710714
[TBL] [Abstract][Full Text] [Related]
11. L1CAM Expression is Related to Non-Endometrioid Histology, and Prognostic for Poor Outcome in Endometrioid Endometrial Carcinoma.
Geels YP; Pijnenborg JM; Gordon BB; Fogel M; Altevogt P; Masadah R; Bulten J; van Kempen LC; Massuger LF
Pathol Oncol Res; 2016 Oct; 22(4):863-8. PubMed ID: 26891628
[TBL] [Abstract][Full Text] [Related]
12. p53, Pirh2, and L1CAM as Promising Prognostic Biomarkers of Endometrial Carcinoma: An Immunohistochemical and Genetic Study.
Abdelrahman AE; Salem A; Al Attar AZ; Elsebai E; Samy W; Ibrahim MA; Ibrahim HM
Appl Immunohistochem Mol Morphol; 2022 Nov-Dec 01; 30(10):713-725. PubMed ID: 36251972
[TBL] [Abstract][Full Text] [Related]
13. Prognostic refinement of NSMP high-risk endometrial cancers using oestrogen receptor immunohistochemistry.
Vermij L; Jobsen JJ; León-Castillo A; Brinkhuis M; Roothaan S; Powell ME; de Boer SM; Khaw P; Mileshkin LR; Fyles A; Leary A; Genestie C; Jürgenliemk-Schulz IM; Crosbie EJ; Mackay HJ; Nijman HW; Nout RA; Smit VTHBM; Creutzberg CL; Horeweg N; Bosse T;
Br J Cancer; 2023 Mar; 128(7):1360-1368. PubMed ID: 36690721
[TBL] [Abstract][Full Text] [Related]
14. Integrated Biomarker Analysis Reveals L1CAM as a Potential Stratification Marker for No Specific Molecular Profile High-Risk Endometrial Carcinoma.
Ravaggi A; Capoferri D; Ardighieri L; Ghini I; Ferrari F; Romani C; Bugatti M; Zanotti L; Vrede S; Tognon G; Pijnenborg JMA; Sartori E; Calza S; Bignotti E; Odicino F
Cancers (Basel); 2022 Nov; 14(21):. PubMed ID: 36358847
[TBL] [Abstract][Full Text] [Related]
15. Limited impact of intratumour heterogeneity on molecular risk assignment in endometrial cancer.
van Esterik M; Van Gool IC; de Kroon CD; Nout RA; Creutzberg CL; Smit VTHBM; Bosse T; Stelloo E
Oncotarget; 2017 Apr; 8(15):25542-25551. PubMed ID: 28424422
[TBL] [Abstract][Full Text] [Related]
16. Comprehensive immunomolecular profiling of endometrial carcinoma: A tertiary retrospective study.
Victoor J; Borght SV; Spans L; Lehnert S; Brems H; Laenen A; Vergote I; Van Gorp T; Van Nieuwenhuysen E; Han S; Timmerman S; Van Rompuy AS; Vanden Bempt I
Gynecol Oncol; 2021 Sep; 162(3):694-701. PubMed ID: 34253388
[TBL] [Abstract][Full Text] [Related]
17. Molecular classification defines outcomes and opportunities in young women with endometrial carcinoma.
Britton H; Huang L; Lum A; Leung S; Shum K; Kale M; Burleigh A; Senz J; Yang W; McConechy M; Kommoss S; Brucker S; Talhouk A; Gilks CB; McAlpine JN
Gynecol Oncol; 2019 Jun; 153(3):487-495. PubMed ID: 30922603
[TBL] [Abstract][Full Text] [Related]
18. Molecular subtypes of clear cell carcinoma of the endometrium: Opportunities for prognostic and predictive stratification.
Kim SR; Cloutier BT; Leung S; Cochrane D; Britton H; Pina A; Storness-Bliss C; Farnell D; Huang L; Shum K; Lum A; Senz J; Lee CH; Gilks CB; Hoang L; McAlpine JN
Gynecol Oncol; 2020 Jul; 158(1):3-11. PubMed ID: 32331700
[TBL] [Abstract][Full Text] [Related]
19. The prognostic significance of positive peritoneal cytology in endometrial cancer and its correlations with L1-CAM biomarker.
Vizza E; Mancini E; Laquintana V; Loria R; Carosi M; Baiocco E; Cicchillitti L; Piaggio G; Patrizi L; Sperduti I; Zampa A; Cutillo G; Falcioni R; Corrado G
Surg Oncol; 2019 Mar; 28():151-157. PubMed ID: 30851892
[TBL] [Abstract][Full Text] [Related]
20. Evaluating L1CAM expression in human endometrial cancer using qRT-PCR.
Notaro S; Reimer D; Duggan-Peer M; Fiegl H; Wiedermair A; Rössler J; Altevogt P; Marth C; Zeimet AG
Oncotarget; 2016 Jun; 7(26):40221-40232. PubMed ID: 27233077
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
